trending Market Intelligence /marketintelligence/en/news-insights/trending/ne2n_-nnngapteqp-aopoa2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

BriaCell raises funds for product pipeline

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

BriaCell raises funds for product pipeline

BriaCell Therapeutics Corp. closed a placement of 43,072,322 company units priced 10 Canadian cents each, raising C$4.3 million in the process.

Each unit consisted of a common share and a warrant to buy an additional stock for 14 Canadian cents apiece.

U.S. biotech funds Brio Capital Master Fund Ltd., Efrat Investments LLC and Mario Family Partners LP participated in the unit offering.

In a separate placement, BriaCell issued US$800,000 worth of debt in the form of 5% unsecured notes that can be converted into common shares of the company.

The biotechnology company will use the net proceeds to advance its product pipeline, which includes a treatment for breast cancer.